Cargando…

Radiomic Feature-Based Nomogram: A Novel Technique to Predict EGFR-Activating Mutations for EGFR Tyrosin Kinase Inhibitor Therapy

OBJECTIVES: To develop and validate a radiomic feature-based nomogram for preoperative discriminating the epidermal growth factor receptor (EGFR) activating mutation from wild-type EGFR in non-small cell lung cancer (NSCLC) patients. MATERIAL: A group of 301 NSCLC patients were retrospectively revie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weng, Qiaoyou, Hui, Junguo, Wang, Hailin, Lan, Chuanqiang, Huang, Jiansheng, Zhao, Chun, Zheng, Liyun, Fang, Shiji, Chen, Minjiang, Lu, Chenying, Bao, Yuyan, Pang, Peipei, Xu, Min, Mao, Weibo, Wang, Zufei, Tu, Jianfei, Huang, Yuan, Ji, Jiansong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377542/ https://www.ncbi.nlm.nih.gov/pubmed/34422624 http://dx.doi.org/10.3389/fonc.2021.590937

Ejemplares similares

Precise prediction of the sensitivity of platinum chemotherapy in SCLC: Establishing and verifying the feasibility of a CT-based radiomics nomogram
por: Su, Yanping, et al.
Publicado: (2023)

A Radiomics Signature-Based Nomogram to Predict the Progression-Free Survival of Patients With Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation
por: Fang, Shiji, et al.
Publicado: (2021)

Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE
por: Kong, Chunli, et al.
Publicado: (2021)

A radiomic nomogram based on arterial phase of CT for differential diagnosis of ovarian cancer
por: Hu, Yumin, et al.
Publicado: (2021)

Triptonide Modulates MAPK Signaling Pathways and Exerts Anticancer Effects via ER Stress-Mediated Apoptosis Induction in Human Osteosarcoma Cells
por: Zheng, Liyun, et al.
Publicado: (2020)

MicroRNA‐155‐5p suppresses PD‐L1 expression in lung adenocarcinoma
por: Huang, Jiansheng, et al.
Publicado: (2020)

ZFP36 Binds With PRC1 to Inhibit Tumor Growth and Increase 5-Fu Chemosensitivity of Hepatocellular Carcinoma
por: Chen, Weiqian, et al.
Publicado: (2020)

Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study
por: Zheng, Liyun, et al.
Publicado: (2021)

Predictive Models for HCC Prognosis, Recurrence Risk, and Immune Infiltration Based on Two Exosomal Genes: MYL6B and THOC2
por: Zhu, Jinyu, et al.
Publicado: (2021)

A role for the NPM1/PTPN14/YAP axis in mediating hypoxia-induced chemoresistance to sorafenib in hepatocellular carcinoma
por: Zhang, Dengke, et al.
Publicado: (2022)

Evaluation of a Chest Circumference-Adapted Protocol for Low-Dose 128-Slice Coronary CT Angiography with Prospective Electrocardiogram Triggering
por: Lu, Chenying, et al.
Publicado: (2015)

CPEB1 mediates hepatocellular carcinoma cancer stemness and chemoresistance
por: Xu, Min, et al.
Publicado: (2018)

TACE responser NDRG1 acts as a guardian against ferroptosis to drive tumorgenesis and metastasis in HCC
por: Tang, Bufu, et al.
Publicado: (2023)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Posterior mediastinal ectopic meningioma: a case report
por: Lu, Chenying, et al.
Publicado: (2015)

Therapeutic Potential of Triptolide as an Anti-Inflammatory Agent in Dextran Sulfate Sodium-Induced Murine Experimental Colitis
por: Tang, Bufu, et al.
Publicado: (2020)

Correction to: Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma
por: Lu, Chenying, et al.
Publicado: (2020)

Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma
por: Lu, Chenying, et al.
Publicado: (2020)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression
por: Chen, Minjiang, et al.
Publicado: (2018)

Compound 15c, a Novel Dual Inhibitor of EGFR(L858R/T790M) and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers
por: Chen, Gaozhi, et al.
Publicado: (2020)

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
por: Kim, Hyungjin, et al.
Publicado: (2017)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Targeted xCT‐mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti‐PD‐1/L1 Response
por: Tang, Bufu, et al.
Publicado: (2022)

Diagnosis and prognosis models for hepatocellular carcinoma patient’s management based on tumor mutation burden
por: Tang, Bufu, et al.
Publicado: (2021)

Cathepsin S attenuates endosomal EGFR signalling: A mechanical rationale for the combination of cathepsin S and EGFR tyrosine kinase inhibitors
por: Huang, Chien-Chang, et al.
Publicado: (2016)

High expression of angiogenic factor AGGF1 is an independent prognostic factor for hepatocellular carcinoma
por: Tu, Jianfei, et al.
Publicado: (2017)

Precision interventional radiology
por: Ji, Jiansong, et al.
Publicado: (2021)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
por: Li, Chenguang, et al.
Publicado: (2018)

CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway
por: Zhao, Zhongwei, et al.
Publicado: (2020)

Using contrast-enhanced CT and non-contrast-enhanced CT to predict EGFR mutation status in NSCLC patients—a radiomics nomogram analysis
por: Yang, Xiaoyan, et al.
Publicado: (2021)

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC
por: Zhang, Yongchang, et al.
Publicado: (2021)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

EGFR inhibition attenuates diabetic nephropathy through decreasing ROS and endoplasmic reticulum stress
por: Xu, Zheng, et al.
Publicado: (2017)

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
por: Karamouzis, M V, et al.
Publicado: (2007)

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
por: Costa, Daniel B, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_cucihsqmc4bt5lhgovs5dm8ldd